Stay updated with breaking news from Enteric Hyperoxaluria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported...
Synlogic Reports First Quarter Financial Results and Provides Business Update - Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension to 2H 2023 - - Management to host conference call and webcast at 8:30 a.m. ET today - News provided by Share this article Share this article CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a ...
Synlogic Announces Pricing of Public Offering of Common Stock News provided by Share this article CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $3.00 per share. The gross proceeds to Synlogic from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Synlogic, are expected to be $3...
Synlogic Announces Proposed Public Offering of Common Stock News provided by Share this article Share this article CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Synlogic. Synlogic intends to grant the underwriter a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common...
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences News provided by Share this article Share this article CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industry conferences: 20 th Annual Needham Virtual Healthcare Conference: Dr. Brennan and Daniel Rosan, SV...